BioSpace News Archive

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it plans to resume its clinical activities following the gradual return to elective procedures across the nation.

Robust Angel Investor-led Series A expected to fully fund Phase 1/2 clinical study for lead surgical nerve-targeting candidate

Study by CHOP researchers finds debilitating lawnmower injuries continue to occur throughout U.S., despite improvements in lawnmower design

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab

Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on therapeutics for acute care settings, today announced that due to the emerging health impact of the coronavirus pandemic, the Company has changed the location of its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) to its corporate headquarters at 490 Lapp Road, Malvern, Pennsylvania 19355.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Christine Matthews as the company’s chief financial officer (CFO).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19

Company expects to create new job opportunities in St. Paul, MN, Northridge, CA and UK [01-May-2020] ST. PAUL, Minn. , May 1, 2020 /PRNewswire/ -- Kindeva Drug Delivery, formerly 3M Drug Delivery Systems, today announced its launch as an independent company following the acquisition by Altaris Capital Partners in a transaction valued at $650 million . As part of t

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced a time change for its first quarter financial results conference call on Wednesday, May 6, 2020.